Reliable and transparent financial news
Contributor's Links: SmarterAnalyst

Smarter Analyst was established to fill a gap in financial reporting for sell-side investors, where they can read exclusive reports in real time. Smarter Analyst provides coverage of equities research, unique analyst insights, and outstanding articles from knowledgeable contributors, in addition ... more

ALL CONTRIBUTIONS

Lisa M Jones’ Q4 Stock Picks: NVIDIA Corporation, Micron Technology, Inc., And Apple Inc.
While the market is very bullish on Micron, Jones drastically cut the fund’s Micron position by over 80%. The fund’s remaining position in the stock of 616,386 shares worth $13.51 million have gained 16.65% since the last filing date.
Read
3 Reasons To Consider Snap Inc (SNAP) Shares
Camera company Snap Inc drove the market into a frenzy with its IPO which was the biggest since Alibaba back in 2014. Snapchat, which is famous for its disappearing message app, sold over 200 million shares in its IPO raising $3.4 billion
Read
Mast Therapeutics Inc. Announces 4Q And Full Year 2016 Financial & Operating Results
Mast Therapeutics Inc. reported net loss for the fourth quarter of 2016 was $6.0 million, or $0.02 per share (basic and diluted), compared to a net loss of $10.2 million, or $0.06 per share (basic and diluted), for the same period in 2015.
Read
Monday’s Biotech Insights: Concert Pharmaceuticals Inc (CNCE), TG Therapeutics Inc (TGTX)
CNCE shares skyrocketed today following the news that Vertex Pharmaceuticals (NASDAQ:VRTX) will acquire Concert’s deuterated Kalydeco variant, CTP-656, for $160 million upfront with up to $90 million in milestones.
Read
Apple Inc. Installed Base Growth Remains Robust, Micron Technology, Inc. Preannouncement Indicates Strong Strides Into Q3
As BMO delves closer into Apple Inc. and its iPhone installed base while Barclays sings the praises of the recent preannouncement from Micron Technology, Inc., one thing remains clear for both companies: good things await.
Read
Valeant Pharmaceuticals Intl. Inc. Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L’Oréal
Valeant Pharmaceuticals Intl Inc. announced that it has completed the previously announced sale of its CeraVe, AcneFree and AMBI skincare brands to L’Oréal for $1.3 billion in cash.
Read

STOCKS I FOLLOW

AUMN Golden Minerals Company
DNOW NOW Inc.
IEP Icahn Enterprises L.P.
SDVI SIGNATURE DEVICES
SURP SOEFL Inc

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications